keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic ductal adenocarcinoma

keyword
https://www.readbyqxmd.com/read/29679211/surgery-after-folfirinox-treatment-for-locally-advanced-and-borderline-resectable-pancreatic-cancer-increase-in-tumour-attenuation-on-ct-correlates-with-r0-resection
#1
Giovanni Marchegiani, Valentina Todaro, Enrico Boninsegna, Riccardo Negrelli, Binit Sureka, Debora Bonamini, Roberto Salvia, Riccardo Manfredi, Roberto Pozzi Mucelli, Claudio Bassi
OBJECTIVES: To assess factors associated with radical resection (R0) of pancreatic ductal adenocarcinoma (PDAC) after induction treatment with FOLFIRINOX. METHODS: Patients with either locally advanced (LA) and borderline resectable (BR) PDAC undergoing surgical exploration after FOLFIRINOX were retrospectively enrolled. Two pancreatic radiologists reviewed the CT blinded to the final outcome and assessed chemotherapy response and resectability. Patients were then divided into R0 resected (group A) and not resected/R1 resected (group B), which were compared...
April 20, 2018: European Radiology
https://www.readbyqxmd.com/read/29676354/diagnostic-and-prognostic-impact-of-mucin-1-6-expression-in-non-small-cell-lung-cancer
#2
William Sterlacci, Michael Fiegl, Lothar Veits, Alexandar Tzankov
Background: The prognostic significance and clinico-pathological characterization of mucin (MUC) expression in non-small cell lung cancer (NSCLC) is controversial and little studied. Aims: This study aims at elucidating this issue on the largest and most detailed cohort so far. Settings and Design: We examined the expression of MUC 1, 2, 4, 5AC and 6 on 371, well documented, surgically resected NSCLC cases. Materials and Methods: Immunohistochemical results were correlated with several of our previously studied, relevant parameters on this cohort including a follow-up period of up to 20 years...
April 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29675938/value-of-additional-endoscopic-ultrasonography-for-surveillance-after-surgical-removal-of-intraductal-papillary-mucinous-neoplasms
#3
Ken Kamata, Mamoru Takenaka, Kosuke Minaga, Shunsuke Omoto, Takeshi Miyata, Kentaro Yamao, Hajime Imai, Atsushi Nakai, Hidekazu Tanaka, Yasutaka Chiba, Tomohiro Watanabe, Toshiharu Sakurai, Naoshi Nishida, Takaaki Chikugo, Ippei Matsumoto, Yoshifumi Takeyama, Masayuki Kitano, Masatoshi Kudo
BACKGROUND AND AIMS: This study evaluated the utility of endoscopic ultrasonography (EUS), combined with contrast-enhanced harmonic EUS (CH-EUS), for surveillance of the remnant pancreas after surgery for intraductal papillary mucinous neoplasm (IPMN). METHODS: This was a single-center, retrospective, descriptive study. A total of 134 consecutive patients who underwent surgical resection for IPMN between April 2009 and March 2015 were evaluated. The rates of recurrence and development of IPMN-concomitant pancreatic ductal adenocarcinoma (PDAC) during follow-up were assessed...
April 19, 2018: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/29675761/vitamin-d-supplementation-is-a-promising-therapy-for-pancreatic-ductal-adenocarcinoma-in-conjunction-with-current-chemoradiation-therapy
#4
Yosuke Mukai, Daisaku Yamada, Hidetoshi Eguchi, Yoshifumi Iwagami, Tadafumi Asaoka, Takehiro Noda, Koichi Kawamoto, Kunihito Gotoh, Shogo Kobayashi, Yutaka Takeda, Masahiro Tanemura, Masaki Mori, Yuichiro Doki
BACKGROUND: The cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma (PDAC) are well known to play a dominant role in distant metastasis. Nevertheless, the effect on CAFs with current chemoradiation therapies remains uncertain. OBJECTIVE: This study aimed to reveal the role of CAFs under current chemoradiation therapy (CRT) and investigate the factors regulating CAFs. METHODS: α-SMA-positive cells in 86 resected PDAC specimens with/without preoperative CRT were evaluated by immunohistochemistry...
April 19, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29675111/a-survival-model-in-locally-advanced-and-metastatic-pancreatic-ductal-adenocarcinoma
#5
Yi Wang, Xiuying Xiao, Tianyi Wang, Lin Li, Yue Zhu, Haiyan Xu, Yuening Chu, Feng Jiao, Jiujie Cui, Liwei Wang
The prognostic role of serum LDH, CA19-9, CRP and ALB in PDAC patients are controversial. In contrast to single factor, there is much less information about the prognostic value of the combination of the four factors in locally advanced and metastatic PDAC patients. It's essential to set up a survival model with the combination of tumor metabolism, tumor biomarker, systemic inflammation and nutritional status to eliminate the prognostic inaccuracy in single biomarker. 94 advanced PDAC patients who received palliative chemotherapy from 2009 to 2017 were recruited for this study...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29675033/identification-and-validation-of-a-diagnostic-and-prognostic-multi-gene-biomarker-panel-for-pancreatic-ductal-adenocarcinoma
#6
Hagen Klett, Hannah Fuellgraf, Ella Levit-Zerdoun, Saskia Hussung, Silke Kowar, Simon Küsters, Peter Bronsert, Martin Werner, Uwe Wittel, Ralph Fritsch, Hauke Busch, Melanie Boerries
Late diagnosis and systemic dissemination essentially contribute to the invariably poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Therefore, the development of diagnostic biomarkers for PDAC are urgently needed to improve patient stratification and outcome in the clinic. By studying the transcriptomes of independent PDAC patient cohorts of tumor and non-tumor tissues, we identified 81 robustly regulated genes, through a novel, generally applicable meta-analysis. Using consensus clustering on co-expression values revealed four distinct clusters with genes originating from exocrine/endocrine pancreas, stromal and tumor cells...
2018: Frontiers in Genetics
https://www.readbyqxmd.com/read/29672406/number-of-examined-lymph-nodes-and-nodal-status-assessment-in-distal-pancreatectomy-for-body-tail-ductal-adenocarcinoma
#7
Giuseppe Malleo, Laura Maggino, Cristina R Ferrone, Giovanni Marchegiani, Mari Mino-Kenudson, Paola Capelli, Borislav Rusev, Keith D Lillemoe, Claudio Bassi, Carlos Fernàndez-Del Castillo, Roberto Salvia
OBJECTIVE: First, to assess the impact of the number of examined lymph nodes (ELNs) on staging and survival after distal pancreatectomy (DP) for pancreatic adenocarcinoma (PDAC). Second, to identify the minimum number of ELNs (MNELNs) ensuring an accurate detection of nodal involvement. Third, to reappraise the role of lymph node (LN) parameters, including N-status and lymph node ratio (LNR). BACKGROUND: In contrast with pancreatoduodenectomy, information on LN staging and the MNELN required in DP is lacking...
April 18, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29671412/possible-molecular-markers-for-the-diagnosis-of-pancreatic-ductal-adenocarcinoma
#8
Quan Shen, Miao Yu, Jiang-Kun Jia, Wen-Xi Li, Yu-Wei Tian, Huan-Zhou Xue
BACKGROUND We aimed to identify pivotal genes and pathways involved in pancreatic ductal adenocarcinoma (PDAC), and explore possible molecular markers for the early diagnosis of the disease. MATERIAL AND METHODS The array data of GSE74629, including 34 PDAC samples and 16 healthy samples, was downloaded from GEO (Gene Expression Omnibus) database. Then, the DEGs (differentially expressed genes) in PDAC samples were compared with healthy samples using limma (linear models for microarray). Gene functional interaction networks were analyzed with Cytoscape and ReactomeFIViz...
April 19, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29670543/phosphoinositide-3-kinase-signaling-pathway-in-pancreatic-ductal-adenocarcinoma-progression-pathogenesis-and-therapeutics
#9
REVIEW
Divya Murthy, Kuldeep S Attri, Pankaj K Singh
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by its sudden manifestation, rapid progression, poor prognosis, and limited therapeutic options. Genetic alterations in key signaling pathways found in early pancreatic lesions are pivotal for the development and progression of pancreatic intraepithelial neoplastic lesions into invasive carcinomas. More than 90% of PDAC tumors harbor driver mutations in K-Ras that activate various downstream effector-signaling pathways, including the phosphoinositide-3-kinase (PI3K) pathway...
2018: Frontiers in Physiology
https://www.readbyqxmd.com/read/29670173/overexpression-of-her2-in-the-pancreas-promotes-development-of-intraductal-papillary-mucinous-neoplasms-in-mice
#10
Wataru Shibata, Hiroto Kinoshita, Yohko Hikiba, Takeshi Sato, Yasuaki Ishii, Soichiro Sue, Makoto Sugimori, Nobumi Suzuki, Kosuke Sakitani, Hideaki Ijichi, Ryutaro Mori, Itaru Endo, Shin Maeda
Pancreatic ductal adenocarcinoma (PDA) has a 5-year survival rate of less than 5% and is the sixth leading cause of cancer death. Although KRAS mutations are one of the major driver mutations in PDA, KRAS mutation alone is not sufficient to induce invasive pancreatic cancer in mice model. HER2, also known as ERBB2, is a receptor tyrosine kinase, and overexpression of HER2 is associated with poor clinical outcomes in pancreatic cancer. However, no report has shown whether HER2 and its downstream signaling contributes to the pancreatic cancer development...
April 18, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29670110/tumor-associated-macrophages-promote-progression-and-the-warburg-effect-via-ccl18-nf-kb-vcam-1-pathway-in-pancreatic-ductal-adenocarcinoma
#11
Huilin Ye, Quanbo Zhou, Shangyou Zheng, Guolin Li, Qing Lin, Lusheng Wei, Zhiqiang Fu, Bin Zhang, Yimin Liu, Zhihua Li, Rufu Chen
Tumor-associated macrophages (TAMs) are frequently found near pancreatic cancer cells, but it is uncertain whether they are involved in pancreatic cancer progression and the Warburg effect. Here, we show that CCL18 secreted by TAMs facilitates malignant progression and induced a glycolytic phenotype in pancreatic cancer, partially owing to paracrine induction of VCAM-1 in pancreatic cancer cells. Reciprocally, VCAM-1-induced lactate production from pancreatic cancer cells with enhanced aerobic glycolysis activates macrophages to a TAM-like phenotype, forming a positive feedback loop...
April 18, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29670075/the-novel-trail-receptor-agonist-apg350-exerts-superior-therapeutic-activity-in-pancreatic-cancer-cells
#12
Karen Legler, Charlotte Hauser, Jan-Hendrik Egberts, Anna Willms, Carola Heneweer, Susann Boretius, Christoph Röcken, Claus-Christian Glüer, Thomas Becker, Michael Kluge, Oliver Hill, Christian Gieffers, Harald Fricke, Holger Kalthoff, Johannes Lemke, Anna Trauzold
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has raised attention as a novel anticancer therapeutic as it induces apoptosis preferentially in tumor cells. However, first-generation TRAIL-receptor agonists (TRAs), comprising recombinant TRAIL and agonistic receptor-specific antibodies, have not demonstrated anticancer activity in clinical studies. In fact, cancer cells are often resistant to conventional TRAs. Therefore, in addition to TRAIL-sensitizing strategies, next-generation TRAs with superior apoptotic activity are warranted...
April 18, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29668571/evaluating-for-pseudoprogression-in-colorectal-and-pancreatic-tumors-treated-with-immunotherapy
#13
Christine M Parseghian, Madhavi Patnana, Priya Bhosale, Kenneth R Hess, Ya-Chen Tina Shih, Bumyang Kim, Scott Kopetz, Michael J Overman, Gauri R Varadhachary, Milind Javle, Aung Naing, Sarina Piha-Paul, David Hong, Hung Le, Vivek Subbiah, Shubham Pant
Pseudoprogression has been observed in patients with various tumor types treated with immunotherapy. However, the frequency of pseudoprogression is unknown in gastrointestinal malignancies. Metastatic colorectal cancer (mCRC) and advanced pancreatic ductal adenocarcinoma (PDAC) patients who progressed on treatment with immunotherapy beyond RECIST version 1.1 criteria were analyzed. Degree of progression, tumor markers, time to progression, overall survival, Eastern Cooperative Oncology Group Performance Status (ECOG PS), and costs were analyzed for patients treated beyond progression (TBP) and not treated beyond progression...
April 17, 2018: Journal of Immunotherapy
https://www.readbyqxmd.com/read/29668413/pancreatic-adenocarcinoma-staging-in-the-era-of-preoperative-chemotherapy-and-radiation-therapy
#14
Marc Zins, Celso Matos, Christophe Cassinotto
Pancreatic ductal adenocarcinoma (PDA) remains among the most challenging malignancies to treat. At diagnosis, the tumor often already extends beyond the confines of the pancreas, spreading to an extent such that primary surgery with curative intent is very rarely feasible. Considerable momentum is now being given to a treatment strategy involving neoadjuvant chemotherapy or chemotherapy and radiation therapy in patients with nonmetastatic PDA. The main advantage of this strategy is better selection of patients likely to benefit from curative-intent surgery through the achievement of negative resection margins...
May 2018: Radiology
https://www.readbyqxmd.com/read/29667116/intraoperative-pancreatic-cancer-detection-using-tumor-specific-multimodality-molecular-imaging
#15
Willemieke S Tummers, Sarah E Miller, Nutte T Teraphongphom, Adam Gomez, Idan Steinberg, David M Huland, Steve Hong, Sri-Rajasekhar Kothapalli, Alifia Hasan, Robert Ertsey, Bert A Bonsing, Alexander L Vahrmeijer, Rutger-Jan Swijnenburg, Teri A Longacre, George A Fisher, Sanjiv S Gambhir, George A Poultsides, Eben L Rosenthal
BACKGROUND: Operative management of pancreatic ductal adenocarcinoma (PDAC) is complicated by several key decisions during the procedure. Identification of metastatic disease at the outset and, when none is found, complete (R0) resection of primary tumor are key to optimizing clinical outcomes. The use of tumor-targeted molecular imaging, based on photoacoustic and fluorescence optical imaging, can provide crucial information to the surgeon. The first-in-human use of multimodality molecular imaging for intraoperative detection of pancreatic cancer is reported using cetuximab-IRDye800, a near-infrared fluorescent agent that binds to epidermal growth factor receptor...
April 17, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29667044/germline-variants-in-pancreatic-cancer-patients-with-a-personal-or-family-history-of-cancer-fulfilling-the-revised-bethesda-guidelines
#16
Akihiro Ohmoto, Chigusa Morizane, Emi Kubo, Erina Takai, Hiroko Hosoi, Yasunari Sakamoto, Shunsuke Kondo, Hideki Ueno, Kazuaki Shimada, Shinichi Yachida, Takuji Okusaka
BACKGROUND: Pancreatic cancer (PC) is categorized as a neoplasm associated with Lynch syndrome; however, the precise proportion of PC patients harboring DNA mismatch repair genes (MMR genes) remains unclear, especially in the Asian population. METHODS: Among 304 Japanese patients with pathologically proven pancreatic ductal adenocarcinoma, we selected 20 (6.6%) patients with a personal or family history involving first- or second-degree relatives fulfilling the revised Bethesda guidelines (RBG), defined as RBG-compatible cases...
April 17, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29665121/homoharringtonine-could-induce-quick-protein-synthesis-of-psmd11-through-activating-mek1-erk1-2-signaling-pathway-in-pancreatic-cancer-cells
#17
Lele Wang, Linlin Zhao, Guo Wei, Dieter Saur, Barbara Seidler, Junyan Wang, Chuanxin Wang, Tonggang Qi
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most devastating disease with the 5-year survival rate less than 6%. In this study, we investigated if inhibiting protein synthesis directly with homoharringtonine (HHT) could induce acute apoptosis in pancreatic cancer cells through quick depletion of multiple short-lived critical members of the central proteome, example, PSMD11(26S proteasome non-ATPase regulatory subunit 11). It was shown that although HHT could inhibit proliferation and growth of MiaPaCa-2 and PANC-1 cells in a time- and dose-dependent manner, only part of pancreatic cancer cells could be induced to die through acute apoptosis...
April 17, 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29664340/pancreatic-ductal-adenocarcinoma-rim-enhancement-at-mr-imaging-predicts-prognosis-after-curative-resection
#18
Sunyoung Lee, Seong Hyun Kim, Hyung Kyu Park, Kee Taek Jang, Jeong Ah Hwang, Seonwoo Kim
Purpose To identify features at preoperative magnetic resonance (MR) imaging that could predict favorable prognosis after curative resection of pancreatic ductal adenocarcinoma (PDAC). Materials and Methods From January 2009 to December 2014, this retrospective study included 143 patients with surgically resected (ie, R0) PDAC who underwent preoperative MR imaging within 1 month before surgery. Clinical-pathologic and MR imaging findings for predicting disease-free survival (DFS) and overall survival (OS) were identified by using a Cox proportional hazards model...
April 17, 2018: Radiology
https://www.readbyqxmd.com/read/29663140/poorly-differentiated-ductal-adenocarcinoma-of-the-pancreas-with-rapid-progression-in-a-young-man
#19
Koji Tezuka, Tomoharu Ishiyama, Akiko Takeshita, Hidekazu Matsumoto, Akira Jingu, Jiro Kikuchi, Hideyuki Yamaya, Rintaro Ohe, Tetsuya Ishizawa
Pancreatic cancer in young adults is very rare. We report a case of young-onset poorly differentiated pancreatic ductal adenocarcinoma with rapid progression and poor prognosis in a 31-year-old Japanese man with no obvious family history of malignancy. Preoperative examinations revealed a mass lesion in the body of the pancreas, accompanied by a slightly dilated main pancreatic duct distal to the mass lesion. Pancreatic cancer with acute pancreatitis was suspected because of an elevation of serum pancreatic enzyme and tumor marker, along with imaging findings...
April 16, 2018: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/29662656/stereotactic-body-radiation-therapy-for-palliative-management-of-pancreatic-adenocarcinoma-in-elderly-and-medically-inoperable-patients
#20
John F Ryan, Lauren M Rosati, Vincent P Groot, Dung T Le, Lei Zheng, Daniel A Laheru, Eun J Shin, Juan Jackson, Joseph Moore, Amol K Narang, Joseph M Herman
Stereotactic body radiation therapy (SBRT) represents a promising treatment option for patients with localized pancreatic ductal adenocarcinoma (PDAC) who cannot tolerate surgical therapy. We retrospectively reviewed the records of patients with localized PDAC treated with SBRT at our institution between 2010 and 2016 to identify patients deemed medically inoperable due to poor performance status, advanced age, and/or comorbid conditions. Overall survival (OS), progression-free survival (PFS), and local progression-free survival (LPFS) were estimated using Kaplan-Meier curves...
March 27, 2018: Oncotarget
keyword
keyword
89776
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"